Federal Register notice: FDA extends the comment period for a 6/15 notice on: Exemption from Premarket Notification: Powered Patient Transports.
Federal Register notice: FDA and the Clinical Trials Transformation Initiative request applications for patient advocates interested in participating ...
FDA revises a Manual of Policies and Procedures (MAPP) entitled Generic Drug Labeling Revisions Under Section 505(j)(10) of the Federal Food, Drug, an...
Bristol Myers Squibb withdraws an indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma who were previously t...
FDA Review posts the Federal Register notices for the week ending 7/23/2021.
Federal Register notice: FDA updates its listing of emergency use authorizations granted during the Covid-19 public health emergency.
Federal Register notice: FDA updates its listing of guidance documents related to the Covid-19 public health emergency.
FDA approves AbbVies Dalvance (dalbavancin) for treating acute bacterial skin and skin structure infections in pediatric patients.